Ocifisertib hydrochloride
Based on 9 publication(s) in Google Scholar
Ocifisertib hydrochloride (CFI-400945 hydrochloride) is the hydrochloride salt form of Ocifisertib (HY-12300). Ocifisertib hydrochloride is an orally active PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM. Ocifisertib hydrochloride inhibits growth of various cancer cells, arrests cell cycles at G2/M phase, and induces apoptosis. Ocifisertib hydrochloride exhibits antitumor efficacy in mouse model.
For research use only. We do not sell to patients.
- Purity : 98.29%
- CAS No.: 1338799-83-9
- Formula: C33H35ClN4O3
- Molecular Weight:571.11
-
Storage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ocifisertib hydrochloride
More- Nat Nanotechnol. 2021 Jul;16(7):830-839. [Abstract]
- Cell Death Differ. 2026 May 25. [Abstract]
- J Integr Plant Biol. 2026 Apr 2. [Abstract]
- Cell Chem Biol. 2026 Aug 20;33(8):1117-1134.e6.
- Int J Mol Med. 2021 Jan;47(1):151-160. [Abstract]
- Cancer Cell Int. 2026 Jun 18.
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883. [Abstract]
- Ir J Med Sci. 2023 Apr;192(2):561-567. [Abstract]
Customer Validation & Images
-
WB
-
WB
-
Cell Imaging/Staining
-
WB
-
WB
Biological Activity
Description
IC50 & Target
|
PLK4 2.8 nM (IC50) |
TRKA 6 nM (IC50) |
TRKB 9 nM (IC50) |
TIE2/TEK 22 nM (IC50) |
AURKB/INCENP 98 nM (IC50) |
AURKA 140 nM (IC50) |
Chemical Information
-
CAS No. 1338799-83-9
-
Appearance Solid
-
Molecular Weight 571.11
-
Formula C33H35ClN4O3
-
Color White to light yellow
-
SMILES
O=C(NC1=C2C=C(C=C1)OC)[C@@]32[C@@H](C3)C4=CC5=C(C(/C=C/C6=CC=C(C=C6)CN7C[C@H](O[C@H](C7)C)C)=NN5)C=C4.Cl
-
Synonyms
CFI-400945 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. [Abstract]2021 Jul;16(7):830-839. PMID: 33958764 -
Cell Death Differ
GSDME acts as an epigenetic modifier to promote melanoma development via centriole biogenesis regulator PLK4. [Abstract]2026 May 25. PMID: 42185629 -
J Integr Plant Biol
2026 Apr 2. PMID: 41928062 -
-
Int J Mol Med
MicroRNA‑126 suppresses the proliferation and migration of endothelial cells in experimental diabetic retinopathy by targeting polo‑like kinase 4. [Abstract]2021 Jan;47(1):151-160. PMID: 33416109 -
Ocifisertib hydrochloride purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2026 Jun 18.
MCF7 and MCF7-TP53-KO cells were treated with ocifisertib (25 nM), PPM1Di (250 nM) or combination of both for 5 days and cleavage of caspase 7 was assayed by immunoblotting.
-
-
J Cancer Res Clin Oncol
Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing's sarcoma cells. [Abstract]2020 Nov;146(11):2871-2883. PMID: 32770382
Ocifisertib hydrochloride purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883. [Abstract]
Treatment with CFI-400945 and centrinone induced the appearance of the 89 kDa PARP1 cleavage product in a concentration-dependent manner.
Ocifisertib hydrochloride purchased from MedChemExpress. Usage Cited in: J Cancer Res Clin Oncol. 2020 Nov;146(11):2871-2883. [Abstract]
PLK4i induces DNA damage in WE-68 cells. Cells were exposed to CFI-400945 or centrinone for 2 hours. Phosphorylation levels of H2AX were detected by immunoblotting.
-
Ir J Med Sci
PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling. [Abstract]2023 Apr;192(2):561-567. PMID: 35508865
Ocifisertib hydrochloride purchased from MedChemExpress. Usage Cited in: Ir J Med Sci. 2023 Apr;192(2):561-567. [Abstract]
Representative images showing the expression of PLK4, p-PI3K, PI3K, p-AKT, AKT, and GAPDH in RPMI-8226 cells treated with CFI-400945 (200 nM), bortezomib, 740 YP, or a combination thereof, as detected by Western blotting.
Ocifisertib hydrochloride purchased from MedChemExpress. Usage Cited in: Ir J Med Sci. 2023 Apr;192(2):561-567. [Abstract]
Effects of bortezomib, CFI-400945 (200 nM), or their combination on the relative survival rate and TUNEL-positive rate (200× magnification) of RPMI-8226 cells.
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (175.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sampson PB, et al. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5?'-methoxyspiro[cyclopropane-1,3?'-indolin]-2?'-one (CFI-400945) as a potent, orally active antitumor agent. J Med Chem. 2015 Jan 8;58(1):147-69. [Content Brief]
[2]. Mason JM, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7510 mL | 8.7549 mL | 17.5098 mL | 43.7744 mL |
| 5 mM | 0.3502 mL | 1.7510 mL | 3.5020 mL | 8.7549 mL | |
| 10 mM | 0.1751 mL | 0.8755 mL | 1.7510 mL | 4.3774 mL | |
| 15 mM | 0.1167 mL | 0.5837 mL | 1.1673 mL | 2.9183 mL | |
| 20 mM | 0.0875 mL | 0.4377 mL | 0.8755 mL | 2.1887 mL | |
| 25 mM | 0.0700 mL | 0.3502 mL | 0.7004 mL | 1.7510 mL | |
| 30 mM | 0.0584 mL | 0.2918 mL | 0.5837 mL | 1.4591 mL | |
| 40 mM | 0.0438 mL | 0.2189 mL | 0.4377 mL | 1.0944 mL | |
| 50 mM | 0.0350 mL | 0.1751 mL | 0.3502 mL | 0.8755 mL | |
| 60 mM | 0.0292 mL | 0.1459 mL | 0.2918 mL | 0.7296 mL | |
| 80 mM | 0.0219 mL | 0.1094 mL | 0.2189 mL | 0.5472 mL | |
| 100 mM | 0.0175 mL | 0.0875 mL | 0.1751 mL | 0.4377 mL |
Ocifisertib hydrochloride Related Classifications
HY-12300A Related Classifications
Powered by Bioz